Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
319last 24h
2137last 7d
380● bullish (7d)
185● bearish (7d)
204publishers
Zacks96d agobearish
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%Zacks99d agobearish
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue EstimatesUltragenyx (RARE) delivered earnings and revenue surprises of -18.96% and -15.66%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks104d agobearish
Pacira (PCRX) Q1 Earnings Miss EstimatesPacira (PCRX) delivered earnings and revenue surprises of -1.64% and +0.58%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?